Biotest Aktiengesellschaft (BIO.DE)
EUR 41.4
(0.49%)
EUR 41.4
(0.49%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 127 Million EUR | 501.9% |
| 2022 | -31.6 Million EUR | 50.08% |
| 2021 | -63.3 Million EUR | -101.59% |
| 2020 | -31.4 Million EUR | -568.09% |
| 2019 | -4.7 Million EUR | -102.59% |
| 2018 | 181.7 Million EUR | 5291.43% |
| 2017 | -3.5 Million EUR | 92.36% |
| 2016 | -45.8 Million EUR | 44.48% |
| 2015 | -82.5 Million EUR | -529.69% |
| 2014 | 19.2 Million EUR | -40.0% |
| 2013 | 32 Million EUR | -4.21% |
| 2012 | 33.4 Million EUR | -30.62% |
| 2011 | 48.14 Million EUR | 21.94% |
| 2010 | 39.48 Million EUR | 40.92% |
| 2009 | 28.02 Million EUR | -0.35% |
| 2008 | 28.11 Million EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | -100.0% |
| 2004 | 5.85 Million EUR | 11.63% |
| 2003 | 5.24 Million EUR | -73.51% |
| 2002 | 19.79 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 29.5 Million EUR | -23.58% |
| 2024 Q2 | 9.7 Million EUR | -67.12% |
| 2023 Q3 | 114.4 Million EUR | 415.32% |
| 2023 Q1 | -20.4 Million EUR | -916.0% |
| 2023 Q2 | 22.2 Million EUR | 208.82% |
| 2023 Q4 | 38.6 Million EUR | -66.26% |
| 2023 FY | 127 Million EUR | 501.9% |
| 2022 Q4 | 2.5 Million EUR | 117.48% |
| 2022 Q3 | -14.3 Million EUR | 4.67% |
| 2022 Q2 | -15 Million EUR | -206.12% |
| 2022 Q1 | -4.9 Million EUR | 86.04% |
| 2022 FY | -31.6 Million EUR | 50.08% |
| 2021 FY | -63.3 Million EUR | -101.59% |
| 2021 Q1 | -14.1 Million EUR | -3625.0% |
| 2021 Q2 | -4.1 Million EUR | 70.92% |
| 2021 Q3 | -10.1 Million EUR | -146.34% |
| 2021 Q4 | -35.1 Million EUR | -247.52% |
| 2020 FY | -31.4 Million EUR | -568.09% |
| 2020 Q1 | -10.8 Million EUR | -500.0% |
| 2020 Q2 | -5.8 Million EUR | 46.3% |
| 2020 Q3 | -15.1 Million EUR | -160.34% |
| 2020 Q4 | 400 Thousand EUR | 102.65% |
| 2019 Q1 | -1.2 Million EUR | 85.54% |
| 2019 Q3 | -4.9 Million EUR | -253.13% |
| 2019 Q4 | -1.8 Million EUR | 63.27% |
| 2019 FY | -4.7 Million EUR | -102.59% |
| 2019 Q2 | 3.2 Million EUR | 366.67% |
| 2018 Q2 | 158.8 Million EUR | 488.15% |
| 2018 FY | 181.7 Million EUR | 5291.43% |
| 2018 Q1 | 27 Million EUR | 44.39% |
| 2018 Q3 | 5.1 Million EUR | -96.79% |
| 2018 Q4 | -8.3 Million EUR | -262.75% |
| 2017 Q3 | -4.4 Million EUR | -167.69% |
| 2017 Q2 | 6.5 Million EUR | 126.75% |
| 2017 FY | -3.5 Million EUR | 92.36% |
| 2017 Q4 | 18.7 Million EUR | 525.0% |
| 2017 Q1 | -24.3 Million EUR | 44.9% |
| 2016 Q4 | -44.1 Million EUR | -369.15% |
| 2016 Q2 | 5.9 Million EUR | 227.78% |
| 2016 Q1 | 1.8 Million EUR | -67.27% |
| 2016 FY | -45.8 Million EUR | 44.48% |
| 2016 Q3 | -9.4 Million EUR | -259.32% |
| 2015 FY | -82.5 Million EUR | -529.69% |
| 2015 Q3 | -85.8 Million EUR | -2283.33% |
| 2015 Q4 | 5.5 Million EUR | 106.41% |
| 2015 Q2 | -3.6 Million EUR | -357.14% |
| 2015 Q1 | 1.4 Million EUR | 1500.0% |
| 2014 Q4 | -100 Thousand EUR | -101.82% |
| 2014 FY | 19.2 Million EUR | -40.0% |
| 2014 Q1 | 5 Million EUR | -37.5% |
| 2014 Q2 | 8.8 Million EUR | 76.0% |
| 2014 Q3 | 5.5 Million EUR | -37.5% |
| 2013 Q3 | 8.7 Million EUR | 4.82% |
| 2013 FY | 32 Million EUR | -4.21% |
| 2013 Q1 | 7 Million EUR | -60.69% |
| 2013 Q2 | 8.3 Million EUR | 18.57% |
| 2013 Q4 | 8 Million EUR | -8.05% |
| 2012 Q4 | 17.8 Million EUR | 212.42% |
| 2012 FY | 33.4 Million EUR | -30.62% |
| 2012 Q1 | 3.8 Million EUR | -50.32% |
| 2012 Q2 | 6.1 Million EUR | 60.53% |
| 2012 Q3 | 5.7 Million EUR | -6.56% |
| 2011 FY | 48.14 Million EUR | 21.94% |
| 2011 Q4 | 7.64 Million EUR | -71.98% |
| 2011 Q1 | 5.9 Million EUR | -31.28% |
| 2011 Q3 | 27.3 Million EUR | 273.97% |
| 2011 Q2 | 7.3 Million EUR | 23.73% |
| 2010 Q4 | 8.58 Million EUR | 615.42% |
| 2010 Q3 | 1.2 Million EUR | -83.1% |
| 2010 Q2 | 7.1 Million EUR | -68.58% |
| 2010 FY | 39.48 Million EUR | 40.92% |
| 2010 Q1 | 22.6 Million EUR | 673.97% |
| 2009 Q4 | 2.92 Million EUR | -67.91% |
| 2009 FY | 28.02 Million EUR | -0.35% |
| 2009 Q2 | 8.3 Million EUR | 7.79% |
| 2009 Q1 | 7.7 Million EUR | 0.0% |
| 2009 Q3 | 9.1 Million EUR | 9.64% |
| 2008 FY | 28.11 Million EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | -100.0% |
| 2004 FY | 5.85 Million EUR | 11.63% |
| 2003 FY | 5.24 Million EUR | -73.51% |
| 2002 FY | 19.79 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioNTech SE | 930.3 Million EUR | 86.348% |
| CureVac N.V. | -260.16 Million EUR | 148.815% |
| Biotest Aktiengesellschaft | 127 Million EUR | 0.0% |
| BRAIN Biotech AG | -8.27 Million EUR | 1634.002% |
| Formycon AG | 75.79 Million EUR | -67.557% |
| Heidelberg Pharma AG | -20.34 Million EUR | 724.186% |
| Medigene AG | -16.17 Million EUR | 885.065% |